申请人:Fujisawa Pharmaceutical Co., Ltd.
公开号:US04616015A1
公开(公告)日:1986-10-07
New triazine derivatives represented by the formula: ##STR1## wherein R.sup.1 is hydrogen; halogen or hydrazinocarbonyl(lower)alkyl; R.sup.2 is hydrazino; azido; halosulfonyl; mono- or di(lower)alkylamino; mono- or di-(lower alkynylamino; pyridylamino; lower alkylideneamino substituted by furyl pyridyl or aryl; mono- or di-(lower)alkylamino substituted by amino, carboxy, hydroxy, ureido, lower alkoxy, lower alkoxycarbonyl, lower alkoxy(lower)alkoxy, aryl, furyl, pyridyl, phthalimido, or succinimido; N-methyl(lower)alkanoylamino; N-containing, 5- or 6-membered heterocyclic group optionally substituted by oxo, lower alkyl and/or lower alkoxycalbonyl; lower alkoxy substituted by hydroxy and lower alkylamino; or a group of the formula ##STR2## in which R.sup.3 is hydrogen; lower alkyl or ar(lower)alkyl; R.sup.4 is pyridyl; aryl; styryl; alkynyl; lower alkoxycarbonyl; .alpha.-hydroxybenzyl; lower alkanoyl; carboxy; or lower alkyl substituted by halogen, amino, hydroxy, carboxy, lower alkanoyl, lower alkanoyloxy, lower alkoxycarbonyl, morpholino, lower alkoxycarbonylamino, 1-methyl-2-oxo-1,2,3,4-tetrahydroquinolyloxy, mono- or di(lower)alkylamino, piperazinyl being substituted with hydroxy(lower)alkyl or furoyl, or pyrrolidino; and pharmaceutically acceptable salt thereof, which are useful in the treatment of hypertension, thrombosis and ulcer in human beings and animals.
新型三嗪衍生物,其化学式为:##STR1##,其中R.sup.1是氢;卤素或羰基亚硝基(低碳)烷基;R.sup.2是亚硝基;叠氮基;卤磺酰基;单一或二(低碳)烷基氨基;单一或二(低碳)炔基氨基;吡啶基氨基;由呋喃基、吡啶基或芳基取代的低碳烷基亚氨基;由氨基、羧基、羟基、脲基、低碳烷氧基、低碳烷氧基羰基、低碳烷氧基(低碳)烷氧基、芳基、呋喃基、吡啶基、酞酰亚胺基或琥珀酰亚胺基取代的单个或二(低碳)烷基氨基;N-甲基(低碳)烷酰氨基;含有N的5-或6-成员杂环基,可选择由氧基、低碳烷基和/或低碳烷氧基羰基取代;由羟基和低碳烷基氨基取代的低碳烷氧基;或一个由公式##STR2##表示的基团,其中R.sup.3是氢;低碳烷基或芳(低碳)烷基;R.sup.4是吡啶基;芳基;苯乙烯基;炔基;低碳烷氧基羰基;α-羟基苄基;低碳烷酰基;羧基;或由卤素、氨基、羟基、羧基、低碳烷酰基、低碳烷酰氧基、低碳烷氧基羰基、吗啡啉、低碳烷氧基羰基氨基、1-甲基-2-氧代-1,2,3,4-四氢喹诺烷氧基、单一或二(低碳)烷基氨基、哌嗪基(被羟基(低碳)烷基或呋喃酰基取代)或吡咯烷基取代的低碳烷基;以及其药用可接受盐,这些衍生物在治疗人类和动物的 hypertension(高血压)、thrombosis(血栓形成)和ulcer(溃疡)方面是有用的。